4-iodo-2-(4-methoxybenzyloxy)pyridine | 864757-87-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-iodo-2-(4-methoxybenzyloxy)pyridine
• 英文别名: 4-Iodo-2-((4-methoxybenzyl)oxy)pyridine；4-iodo-2-[(4-methoxyphenyl)methoxy]pyridine
• CAS: 864757-87-9
• 化学式: C₁₃H₁₂INO₂
• 分子量: 341.148
• InChiKey: QQYCUJONPPSIIL-UHFFFAOYSA-N

物化性质

• 沸点：
  410.4±35.0 °C(Predicted)
• 密度：
  1.598±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-iodo-2-(4-methoxybenzyloxy)pyridine 、 4-氟苯乙烯 在 bis-triphenylphosphine-palladium(II) chloride potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 以61%的产率得到4-[(E)-2-(4-fluorophenyl)vinyl]-2-(4-methoxybenzyloxy)-pyridine
  参考文献：
  名称：

  PHENYLPYRIDONE DERIVATIVE

  摘要：

  公开号：

  EP1921065B1
• 作为产物：
  描述：

  4-甲氧基苄醇 、 2-氟-4-碘吡啶 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.5h， 以68%的产率得到4-iodo-2-(4-methoxybenzyloxy)pyridine
  参考文献：
  名称：

  PHENYLPYRIDONE DERIVATIVE

  摘要：

  公开号：

  EP1921065B1

文献信息

• [EN] FACTOR IXA INHIBITORS<br/>[FR] INHIBITEURS DU FACTEUR IXA
  申请人：MERCK SHARP & DOHME

  公开号：WO2014120346A1

  公开（公告）日：2014-08-07

  The present invention provides a compound of Formula (I) (structurally represented) wherein R1 is H or C1-6 alkyl, R2 is H or C1-6 alkyl or CH20H, R3 is H or C1-6 alkyl, and R4 is H or C1-6 alkyl, provided that when R1, R2, and R3 are H, R4 is C1-6 alkyl, and when R1, R2, and R4 are H, then R3 is C1-6 alkyl, and when R1, R3, and R4 are H, R2 is C1-6 alkyl or-CH20H, and when R2, R3, and R4 are H, then R1 is C 1-6 alkyl; A is 1 ) a 9-10 membered bicyclic heterocycle having 1-3 heteroatoms independently selected from N, S and 0, which 9-10 membered bicyclic heterocycle is unsubstituted or substituted with R5 and unsubstituted or substituted with R6 and unsubstituted or substituted with NH2, or 2) a 6-9 membered monocyclic or bicyclic carbocyclic ring system unsubstituted or substituted with R5, unsubstituted or substituted with R6, and unsubstituted or substituted with -CH2NH2; and B is 1) a 5- or 6-membered monocyclic heterocycle having 1 or 2 heteroatoms independently selected from N, S or 0, which is unsubstituted or substituted on a carbon or nitrogen atom with R7, unsubstituted or substituted on a carbon or nitrogen atom with R8, and unsubstituted or substituted on a carbon or nitrogen atom with R9, or 2) an 8- or 9-membered fused bicyclic heterocycle having 1, 2 or 3 nitrogen atoms which is unsubstituted or substituted on a carbon or nitrogen atom with R7, and unsubstituted or substituted on a carbon or nitrogen atom with R8; and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses.

  本发明提供了一种式（I）的化合物（结构表示），其中R1为H或C1-6烷基，R2为H或C1-6烷基或CH20H，R3为H或C1-6烷基，R4为H或C1-6烷基，但当R1、R2和R3为H时，R4为C1-6烷基，当R1、R2和R4为H时，R3为C1-6烷基，当R1、R3和R4为H时，R2为C1-6烷基或-CH20H，当R2、R3和R4为H时，R1为C1-6烷基；A为1）具有1-3个异原子（N、S和O中独立选择）的9-10成员双环杂环，该9-10成员双环杂环未取代或取代为R5、未取代或取代为R6、未取代或取代为NH2；或2）未取代或取代为R5、未取代或取代为R6、未取代或取代为-CH2NH2的6-9成员单环或双环碳环系统；B为1）具有1或2个异原子（N、S或O中独立选择）的5-或6成员单环杂环，未取代或在碳或氮原子上取代为R7、未取代或在碳或氮原子上取代为R8、未取代或在碳或氮原子上取代为R9；或2）具有1、2或3个氮原子的8-或9成员融合双环杂环，在碳或氮原子上未取代或取代为R7，并在碳或氮原子上未取代或取代为R8；以及包括一种或多种这些化合物的制药组合物，以及使用这些化合物用于治疗或预防血栓形成的方法。
• Pyridone derivative
  申请人：Otake Norikazu

  公开号：US20070208046A1

  公开（公告）日：2007-09-06

  The invention provides pyridone derivatives represented by a general formula (I) [in the formula, R 1 and R 2 may be same or different and stands for H, etc., or R 1 and R 2 may form an aliphatic nitrogen-containing heterocyclic group together with the N to which they bind; X 1 -X 3 may be same or different and stand for methine or N, provided not all of them simultaneously stand for nitrogen; X 4 -X 7 may be same or different and stand for methine or N, provided that three or more of them do not simultaneously stand for N; Y 1 and Y 3 may be same or different and stand for single bond, —O—, —NR—, —S—, etc; Y 2 stands for lower alkylene, etc.; R stands for H, etc., L stands for methylene; Z 1 and Z 2 may be same or different and stand for single bond or lower alkylene; or R 1 , L and Z 2 may form an aliphatic nitrogen-containing heterocyclic group with the N to which R 1 binds; and Ar stands for aromatic carbocyclic group, etc.].

  该发明提供了由通式（I）表示的吡啶酮衍生物[在公式中，R1和R2可能相同或不同，代表H等，或者R1和R2可能与它们结合的N一起形成一个脂肪族含氮杂环基团；X1-X3可能相同或不同，代表亚甲或N，但不能同时都代表氮；X4-X7可能相同或不同，代表亚甲或N，但不能同时有三个或更多同时代表N；Y1和Y3可能相同或不同，代表单键，-O-，-NR-，-S-等；Y2代表较低的烷基等；R代表H等，L代表亚甲基；Z1和Z2可能相同或不同，代表单键或较低的烷基；或者R1、L和Z2可能与R1结合的N一起形成一个脂肪族含氮杂环基团；Ar代表芳香族碳环基团等]。
• Phenylpyridone derivative
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US07875633B2

  公开（公告）日：2011-01-25

  A compound represented by the formula (I) is contained as an active ingredient: wherein R1 and R2 independently represent a hydrogen atom, a lower alkyl group or the like, or R1 together with a nitrogen atom to which L, Z2 and R1 are attached may form an aliphatic nitrogenated heterocyclic group and R1 and R2 together with a nitrogen atom to which they are attached may form an aliphatic nitrogenated heterocyclic group; X represents a methine group or a nitrogen atom; Y represents —CH2—O—, —CH═CH— or the like; Z1 represents a single bond, a C1-4 alkylene group or the like; Z2 represents a single bond or a C1-4 alkylene group; L represents a methylene group, a C3-8 cycloalkylene group or the like; and Ar represents an aromatic carbocyclic group or the like. The compound is useful as a pharmaceutical for a central nerves system disease, a cardiovascular disease or a metabolic disease.

  化合物的化学式为（I），其中含有一种作为活性成分的化合物：其中R1和R2独立地表示氢原子、低碳烷基或类似物，或者R1与一个与L、Z2和R1相连的氮原子一起可以形成一个脂肪族含氮杂环基团，R1和R2与它们相连的氮原子一起可以形成一个脂肪族含氮杂环基团；X表示一个甲基基团或一个氮原子；Y表示—CH2—O—、—CH═CH—或类似物；Z1表示一个单键、一个C1-4烷基链或类似物；Z2表示一个单键或一个C1-4烷基链；L表示一个亚甲基基团、一个C3-8环烷基链或类似物；Ar表示一个芳香族碳环基团或类似物。该化合物可用作治疗中枢神经系统疾病、心血管疾病或代谢疾病的药物。
• Factor IXa Inhibitors
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20150322056A1

  公开（公告）日：2015-11-12

  The present invention provides a compound of Formula (I) wherein R 1 is H or C 1-6 alkyl, R 2 , is H or C 1-6 alkyl or CH 2 OH, R 3 is H or C 1-6 alkyl, and R 4 is H or C 1-6 alkyl, provided that when R 1 , R 2 , and R 3 are H, R 4 is C 1-6 alkyl, and when R 1 , R 2 , and R 4 are H, then R 3 is C 1-6 alkyl, and when R 1 , R 3 , and R 4 are H, R 2 is C 1-6 alkyl or —CH 2 OH, and when R 2 , R 3 , and R 4 are H, then R 1 is C 1-6 alkyl; A is 1) a 9-10 membered bicyclic heterocycle having 1-3 heteroatoms independently selected from N, S and O, which 9-10 membered bicyclic heterocycle is unsubstituted or substituted with R 5 and unsubstituted or substituted with R 6 and unsubstituted or substituted with NH 2 , or 2) a 6-9 membered monocyclic or bicyclic carbocyclic ring system unsubstituted or substituted with R 5 , unsubstituted or substituted with R 6 , and unsubstituted or substituted with —CH 2 NH 2 ; and B is 1 ) a 5- or 6-membered monocyclic heterocycle having 1 or 2 heteroatoms independently selected from N, S or O, which is unsubstituted or substituted on a carbon or nitrogen atom with R 7 , unsubstituted or substituted on a carbon or nitrogen atom with R 8 , and unsubstituted or substituted on a carbon or nitrogen atom with R 9 , or 2 ) an 8- or 9-membered fused bicyclic heterocycle having 1, 2 or 3 nitrogen atoms which is unsubstituted or substituted on a carbon or nitrogen atom with R 7 , and unsubstituted or substituted on a carbon or nitrogen atom with R 8 ; and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses.

  本发明提供了一种化合物，其化学式为（I），其中R1为H或C1-6烷基，R2为H或C1-6烷基或CH2OH，R3为H或C1-6烷基，R4为H或C1-6烷基，但当R1，R2和R3为H时，R4为C1-6烷基，当R1，R2和R4为H时，R3为C1-6烷基，当R1，R3和R4为H时，R2为C1-6烷基或-CH2OH，当R2，R3和R4为H时，R1为C1-6烷基；A为1）具有1-3个杂原子（N，S和O）的9-10个成员的双环杂环，该9-10个成员的双环杂环未取代或取代为R5，未取代或取代为R6，未取代或取代为NH2，或2）未取代或取代为R5的6-9个成员的单环或双环碳环系统，未取代或取代为R6，未取代或取代为-CH2NH2；B为1）具有1或2个杂原子（N，S或O）的5或6个成员的单环杂环，未在碳或氮原子上取代或取代为R7，未在碳或氮原子上取代或取代为R8，未在碳或氮原子上取代或取代为R9，或2）具有1,2或3个氮原子的8或9个成员的融合双环杂环，未在碳或氮原子上取代或取代为R7，并未在碳或氮原子上取代或取代为R8；以及包括一种或多种上述化合物的制药组合物，以及使用上述化合物用于治疗或预防血栓形成的方法。
• Phenylpyridone Derivative
  申请人：Naya Akira

  公开号：US20090137587A1

  公开（公告）日：2009-05-28

  A compound represented by the formula (I) is contained as an active ingredient: wherein R 1 and R 2 independently represent a hydrogen atom, a lower alkyl group or the like, or R 1 together with a nitrogen atom to which L, Z 2 and R 1 are attached may form an aliphatic nitrogenated heterocyclic group and R 1 and R 2 together with a nitrogen atom to which they are attached may form an aliphatic nitrogenated heterocyclic group; X represents a methine group or a nitrogen atom; Y represents —CH 2 —O—, —CH═CH— or the like; Z 1 represents a single bond, a C 1-4 alkylene group or the like; Z 2 represents a single bond or a C 1-4 alkylene group; L represents a methylene group, a C 3-8 cycloalkylene group or the like; and Ar represents an aromatic carbocyclic group or the like. The compound is useful as a pharmaceutical for a central nerves system disease, a cardiovascular disease or a metabolic disease.

  化合物的化学式为（I），其中包含作为活性成分的化合物：其中R1和R2独立地表示氢原子，低碳基团或类似物，或者R1与L，Z2和R1附着的氮原子一起可以形成脂肪族氮杂环基团，R1和R2与它们附着的氮原子一起可以形成脂肪族氮杂环基团；X表示亚甲基基团或氮原子；Y表示-CH2-O-，-CH═CH-或类似物；Z1表示单键，C1-4烷基撇或类似物；Z2表示单键或C1-4烷基撇；L表示亚甲基基团，C3-8环烷基撇或类似物；Ar表示芳香族碳环基团或类似物。该化合物可用作中枢神经系统疾病、心血管疾病或代谢性疾病的药物。